510
Views
17
CrossRef citations to date
0
Altmetric
Original Articles

Cardiovascular risk factors and lifetime risk estimation in HIV-infected patients under antiretroviral treatment in Spain

, , , , , , , , , , & show all

References

  • Palella FJ Jr, Phair JP. Cardiovascular disease in HIV infection. Curr Opin HIV AIDS. 2011;6:266–271.
  • Duprez DA, Neuhaus J, Kuller LH, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One. 2012;7:e44454.
  • Friis-Moller N, Thiebaut R, Reiss P, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil. 2010;17:491–501.
  • D'Agostino RB Sr. Cardiovascular risk estimation in 2012: lessons learned and applicability to the HIV population. J Infect Dis. 2012;205(Suppl 3):S362–S367.
  • Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med. 2012;366:321–329.
  • Masia M, Perez-Cachafeiro S, Leyes M, et al. Riesgo cardiovascular en pacientes con infección por el virus de la inmunodeficiencia humana en España. Cohorte CoRIS, 2011. Enferm Infecc Microbiol Clin. 2012;30:517–527.
  • Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III), JAMA. 2001;285:2486–2497.
  • Grau M, Marrugat J. Funciones de riesgo en la prevención primaria de las enfermedades cardiovasculares. Rev Esp Cardiol. 2008;61:404–416.
  • Petr EJ, Ayers CR, Pandey A, et al. Perceived lifetime risk for cardiovascular disease (from the Dallas Heart Study). Am J Cardiol. 2014;114:53–58.
  • Catalina-Romero C, Sainz Gutierrez JC, Quevedo AL, et al. Prevalencia de consumo de tabaco en población trabajadora tras la entrada en vigor de la Ley 42/2010. Rev Esp Salud Publica. 2012;86:177–188.
  • Martinez E, Arribas J, López-Aldeguer J. Factors associated with a high cardiovascular risk in HIV infected patients in Spain: a multicenter, nationwide, cross sectional study. Paper presented at: 12th Conference on Retrovirus and Opportunistic Infections; February 22–25, 2005; Boston, MA, USA. Abs # 870.
  • Jerico C, Knobel H, Sorli ML, Montero M, Guelar A, Pedro-Botet J. Prevalencia de factores de riesgo cardiovascular en pacientes con infección por el VIH. Rev Clin Esp. 2006;206:556–559.
  • Garcia-Lazaro M, Rivero RA, Camacho EA, et al. Variabilidad en la valoración del riesgo coronario en pacientes infectados por el virus de la inmunodeficiencia humana. Med Clin (Barc). 2007;129:521–524.
  • Franco M, Cooper R, Bilal U, Fuster V. Control of coronary heart disease risk factors and evidence-based therapies: joint efforts for coronary heart disease prevention in Spain. Rev Esp Cardiol. 2011;64:962–964.
  • Huber M, Ledergerber B, Sauter R, et al. Outcome of smoking cessation counselling of HIV-positive persons by HIV care physicians. HIV Med. 2012;13:387–397.
  • Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292–2333.
  • Worm SW, Kamara DA, Reiss P, et al. Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. AIDS. 2011;25:1497–1504.
  • Freiberg MS, Leaf DA, Goulet JL, et al. The association between the receipt of lipid lowering therapy and HIV status among veterans who met NCEP/ATP III criteria for the receipt of lipid lowering medication. J Gen Intern Med. 2009;24:334–340.
  • Reinsch N, Neuhaus K, Esser S, et al. Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study. Eur J Prev Cardiol. 2012;19:267–274.
  • Ahmed MH, Al-Atta A, Hamad MA. The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges. Expert Opin Pharmacother. 2012;13:1901–1909.
  • Berry JD, Liu K, Folsom AR, et al. Prevalence and progression of subclinical atherosclerosis in younger adults with low short-term but high lifetime estimated risk for cardiovascular disease: the coronary artery risk development in young adults study and multi-ethnic study of atherosclerosis. Circulation. 2009;119:382–389.
  • Hulten E, Villines TC, Cheezum MK, et al. Calcium score, coronary artery disease extent and severity, and clinical outcomes among low Framingham risk patients with low vs high lifetime risk: results from the CONFIRM registry. J Nucl Cardiol. 2014;21:29–37.
  • Marma AK, Lloyd-Jones DM. Systematic examination of the updated Framingham heart study general cardiovascular risk profile. Circulation. 2009;120:384–390.
  • Ferreira-Gonzalez I. The epidemiology of coronary heart disease. Rev Esp Cardiol. 2014;67:139–144.
  • Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Supp 2):S49–73.
  • Nakagawa F, Lodwick RK, Smith CJ, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS. 2012;26:335–343.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.